Agios Pharma upgraded by SVB Leerink with a new price target
$AGIO
Biotechnology: Pharmaceutical Preparations
Health Care
SVB Leerink upgraded Agios Pharma from Mkt Perform to Outperform and set a new price target of $33.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2025 | $58.00 | Buy | H.C. Wainwright |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 10/10/2024 | $51.00 | Outperform | Raymond James |
| 9/27/2024 | $60.00 → $56.00 | Outperform → Market Perform | Leerink Partners |
| 2/8/2024 | Overweight | Cantor Fitzgerald | |
| 2/3/2023 | $41.00 | Overweight | Piper Sandler |
| 11/17/2022 | $17.00 → $32.00 | Sell → Neutral | Goldman |
| 7/27/2022 | $33.00 | Mkt Perform → Outperform | SVB Leerink |
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
PYRUKYND® (mitapivat) is a first-in-class pyruvate kinase (PK) activator, approved by the European Commission for adults with PK deficiency The agreement includes commercialization and distribution rights for potential future indications Furthered by this partnership with Agios, Avanzanite is setting a new paradigm in biotech commercial and distribution partnerships, and in how orphan medicines reach patients across Europe Avanzanite Bioscience B.V. ("Avanzanite"), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (NASDAQ:AGI
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 8:40 a.m. ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in PK activation and is
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in PK activation and is dedicated to devel